Telix Pharmaceuticals Limited
TLX
주식 순위
#4271
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical... Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
주가
$10.88
시가총액
$3.70B
변동 (1일)
1.98%
변동 (1년)
0.55%
국가
AU
거래 Telix Pharmaceuticals Limited (TLX)
카테고리
Healthcare
Telix Pharmaceuticals Limited (TLX)의 영업이익률
October 2026 기준 영업이익률 TTM: -0.73%
Telix Pharmaceuticals Limited의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 -0.73%입니다. 2023년 말 기준 영업이익률은 10.32%였습니다.
Telix Pharmaceuticals Limited의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | -0.73% | -106.96% |
| 2024 | 10.49% | 1.65% |
| 2023 | 10.32% | -122.58% |
| 2022 | -45.71% | -95.73% |
| 2021 | -1,069.60% | 13.21% |
| 2020 | -944.81% | -18.21% |
| 2019 | -1,155.12% | -85.63% |
| 2018 | -8,037.67% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -152.86% |
US
|
|
| -149.01% | 104.12% |
US
|
|
| 25.57% | -135.03% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -139.47% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.